Shire to Relocate More than 500 Jobs to Massachusetts
Shire will establish its US operational headquarters in Massachusetts and relocate staff from Pennsylvania.
Shire plans to relocate more than 500 positions to Massachusetts from its Chesterbrook, Pennsylvania, site and establish Lexington, Massachusetts, as the company’s US operational headquarters. The transition is a continuation of the company’s "One Shire" efficiency program and will streamline business globally through two principal locations-Massachusetts and Switzerland-with support from a limited number of regional and country-based offices around the world.
The company believes that simplifying operations in two principal locations will increase efficiencies, and Shire expects to realize approximately $25 million in annual savings beginning in 2016. This site strategy will also enable greater alignment and execution of priorities between the company’s commercial and R&D teams to more effectively bring innovative products to patients, as well as strengthen collaboration and cross-development of employees, the company said in a press release. Shire plans to move employees in several phases beginning in the first quarter of 2015 and targets completion by the first quarter of 2016.
"Shire has a great opportunity to combine our Chesterbrook and Lexington talent with the leading biotech resources in the Massachusetts area, and we consider ready access to these resources an important element in the future growth of our company,” said CEO Flemming Ornskov, MD, in the press release.
As previously announced, interim CFO James Bowling will be leaving Shire. Jeff Poulton, head of investor relations, will assume the role of interim CFO effective January 1, 2015. The CFO position will be based in Lexington.
Source: Shire
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.
